Back to News
Market Impact: 0.34

Earnings call transcript: NetSol Technologies Q3 2026 sees record revenue but stock dips

NVDANTWKSNEX
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsArtificial IntelligenceFintechAutomotive & EVCurrency & FXInvestor Sentiment & Positioning
Earnings call transcript: NetSol Technologies Q3 2026 sees record revenue but stock dips

NetSol reported record quarterly revenue of $19.8 million, up 13% year over year, with gross margin expanding 560 bps to 55.6% and non-GAAP EBITDA rising 47.8% to $3.4 million. EPS was $0.11 versus $0.12 a year ago, while services revenue fell to $6.3 million due to timing and a prior-year one-time pickup. Management reaffirmed FY2026 revenue guidance of $73 million-$74 million and highlighted continued growth in recurring revenues, AI integration, and the Mercedes-Benz renewal, though shares slipped 2.93% in pre-market trading.

Analysis

NTWK’s print is a classic quality-vs-mask effect: the business is inflecting toward higher-margin recurring revenue, but the market is still anchoring on the mix noise from services and the small EPS step-down. The more important signal is that license monetization from a single anchor relationship is now acting like a bridge to a structurally better base rate, which should make the next few quarters look cleaner on margin even if headline revenue normalizes. That creates a setup where operating leverage can persist without needing outsized top-line surprises. The second-order winner is the software/implementation layer around captive auto finance and dealer workflows, not the OEMs themselves. If Transcend continues to convert implementations into subscription revenue, smaller niche competitors will struggle because the moat becomes switching costs plus embedded workflow data, not feature parity. The U.S. dealer expansion is the key optionality: if even a fraction of the dealer rollout lands, the revenue mix could shift enough to re-rate the stock despite its microcap profile. The main risk is timing, not demand. Services are lumpy and the market may keep discounting the quarter until it sees two consecutive periods without one-time boosts or tax/FX distractions; that suggests a 1-2 quarter digestion phase before the equity fully prices the inflection. A less obvious tail risk is execution concentration: the equity case is increasingly dependent on a handful of large relationships and on management’s ability to turn “pipeline” into cash without receivable elongation. Contrarian view: the selloff may be overdone because investors are penalizing the wrong line item. The real operating signal is margin expansion with recurring revenue growth, which is more valuable than a near-term EPS compare in a business where one contract renewal can distort reported P&L. If the market remains skeptical, that sets up a favorable asymmetry for a patient long, especially if management keeps reiterating guidance and the U.S. rollout data points improve over the next 1-2 quarters.